Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

NCT02620423 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT02620423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02620423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Lead sponsor
Oncolytics Biotech
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
August 31, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma